Evidence map›Paper›PMID 42871108›Full record

ArticleFrontiers in cellular and infection microbiology2026

Emergence of OXA-48-producing

Jorge Rodríguez-Grande, Domingo Fernández-Vecilla, Rosalía Palomino-Cabrera, Samuel García-García, Daniela Vallejo-Iriarte, Nuria Valcárcel-Fraile, María Siller-Ruíz, María Carmen Fariñas, María Pía Roiz Mesones, Jorge Calvo-Montes and 3 more

Abstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jorge Rodríguez-Grande *Servicio de Microbiología, Hospital Universitario Marqués de Valdecilla-Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Domingo Fernández-Vecilla *Servicio de Microbiología, Hospital Universitario Marqués de Valdecilla-Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Rosalía Palomino-Cabrera *Servicio de Microbiología, Hospital Universitario Marqués de Valdecilla-Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Samuel García-GarcíaServicio de Microbiología, Hospital Universitario Marqués de Valdecilla-Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Daniela Vallejo-IriarteServicio de Microbiología, Hospital Universitario Marqués de Valdecilla-Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Nuria Valcárcel-FraileServicio de Microbiología, Hospital Universitario Marqués de Valdecilla-Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
María Siller-RuízServicio de Microbiología, Hospital Universitario Marqués de Valdecilla-Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
María Carmen FariñasConsorcio de Investigación Biomédica en Red (CIBER) de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.
María Pía Roiz MesonesServicio de Microbiología, Hospital Universitario Marqués de Valdecilla-Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Jorge Calvo-MontesServicio de Microbiología, Hospital Universitario Marqués de Valdecilla-Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Alain Ocampo-SosaServicio de Microbiología, Hospital Universitario Marqués de Valdecilla-Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Zaira MoureServicio de Microbiología, Hospital Universitario Marqués de Valdecilla-Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Sergio García-FernándezServicio de Microbiología, Hospital Universitario Marqués de Valdecilla-Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Carbapenemase-producing Methods: A retrospective genomic surveillance study of CP-KP isolates was conducted in Cantabria from 2021 to 2024. Whole-genome sequencing was used to characterize sequence types, resistome, mobilome, virulome, pangenome and phylogenetic relationships. Antimicrobial susceptibility and biofilm production assays were performed. Fourier-transform infrared (FT-IR) spectroscopy combined with machine learning algorithms was used to develop a rapid method for HRCs discrimination. Results: Among 448 non-duplicate CP-KP isolates, Conclusions: Our findings highlight the rapid emergence and regional replacement capacity of the novel OXA-48-producing

Indexed as

beta-LactamasesKlebsiella InfectionsKlebsiella pneumoniaeAnti-Bacterial AgentsBacterial ProteinsBiofilmsDrug Resistance, Multiple, BacterialGenome, BacterialHumansMicrobial Sensitivity TestsPhylogenyPlasmidsRetrospective StudiesSpainWhole Genome SequencingAnti-Bacterial AgentsBacterial Proteinsbeta-Lactamasesoxacillinaseantimicrobial resistancecarbapenemase-producing Klebsiella pneumoniaeFT-IR spectroscopymolecular epidemiologyOXA-48ST307ST5994whole-genome sequencing

Identifiers

PMID42871108
PMCPMC13658459

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.